Norifaz (Risedronate Sodium)

Risedronate sodium, the active ingredient in Norifaz, is a bisphosphonate presented as an oral tablet for oral use. It is indicated for conditions characterized by increased bone resorption, such as osteoporosis and Paget's disease, and is prescribed for adults at risk of fractures.

GNH USA supplies Norifaz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norifaz belongs to the bisphosphonate class and works by reducing excessive bone turnover in several skeletal disorders. - Osteoporosis: lowers the risk of vertebral and hip fractures by inhibiting osteoclast‑mediated bone loss. - Paget's disease of bone: normalises abnormal bone remodeling and reduces bone pain. - Glucocorticoid‑induced osteoporosis: counteracts steroid‑related bone loss and helps maintain bone density.

Risedronate sodium may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal pain: discomfort in the upper abdomen. - Dyspepsia: indigestion or heartburn. - Nausea: feeling of sickness. - Constipation: difficulty passing stool. - Musculoskeletal pain: aches in muscles or joints. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: exposed bone in the oral cavity. - Atypical femur fracture: unusual break of the thigh bone. - Severe esophageal irritation or ulceration. - Acute phase reaction: fever, myalgia, or flu‑like symptoms. - Hypersensitivity: rash, swelling, or anaphylaxis. - Renal impairment: reduced kidney function.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Gastrointestinal disorders: caution in patients with esophageal stricture, reflux, or ulcer disease. - Calcium/Vitamin D status: ensure adequate supplementation to support bone health. - Concomitant NSAIDs or steroids: monitor for additive gastrointestinal irritation. - Pregnancy category unknown: avoid use unless clearly needed and benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Risedronate sodium can interact with several medicines, affecting absorption or increasing toxicity.

Major Interactions (Avoid): - Antacids containing calcium, magnesium, or aluminum: markedly reduce oral absorption of risedronate. - Calcium supplements taken simultaneously: interfere with drug uptake; separate dosing by at least 2 hours. - Oral corticosteroids: increase risk of gastrointestinal ulceration.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Diuretics (loop or thiazide): can affect calcium balance; observe serum electrolytes. - Proton‑pump inhibitors: may alter gastric pH and affect drug dissolution.